1 Min Read
The pharmaceutical industry heads into 2026 carrying strong M&A momentum, a surging Chinese deal landscape and continued buzz around obesity drugs and new modalities. Deals involving Chinese pharma and biotech firms reached $92.2 billion in potential value through November 2025. That’s nearly double the $51.9 billion recorded in 2024, according to Mark Lansdell, Director, Asset… The post Pharma M&A, China deals and GLP-1s: What to watch in 2026 appeared first on Drug Discovery and Development.
Work & Theory on December 21, 2025
Uncategorized